Fluzone Trivalent

Phase 1Biologic

Fluzone Trivalent is one of 18 biologic programs targeting Cutaneous Squamous Cell Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous Squamous Cell CarcinomaRecruiting

Cutaneous Squamous Cell CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

18 competitors in Cutaneous Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Afinitor

Novartis

Approved

1 2

Taxol

Libtayo

9 4

Rapamune

PPrism Pharmaceuticals

Approved

1 5

Rayos

RRoxane Laboratories

Approved

1 6

Keytruda

Merck & Co.

Phase 3

8 7

UNLOXCYT

Sun Pharmaceutical Industries, Inc.

Approved

1 8

Intismeran Autogene

Merck & Co.

Phase 3

1 9

Opdivo

Bristol-Myers Squibb

Phase 2

3 10

Erbitux

IImclone

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cutaneous Squamous Cell Carcinoma1 trial

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

Recruiting·—·Phase 1·NCT06664151·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fluzone Trivalent. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluzone Trivalent compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluzone Trivalent. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dana-Farber Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: DDana-Farber Cancer Institute

Fluzone Trivalent

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cutaneous Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News